Hansa Biopharma: Continuous progress is temporarily blurred by true-up - Redeye

Hansa’s launch progress continues in Q2. The net sales include provisions reflecting an extended period of “true-up” relating to the effect of European sales and volume discounts and refunds pertaining to historical and recent sales. We can expect some future provisions or true-up revisions as volume increases, but these provisions are likely to fade at a later stage of the European launch advances. Our Base Case remains SEK 120 with a Bull Case of SEK 220 and a Bear Case of SEK 15.

Länk till analysen i sin helhet: https://www.redeye.se/research/1025346/hansa-biopharma-continuous-progress-is-temporarily-blurred-by-true-up?utm_source=finwire&utm_medium=RSS